PubMed:7130176 JSONTXT

{"project":"GlyCosmos15-Species","denotations":[{"id":"1","span":{"begin":22,"end":27},"obj":"Species"},{"id":"19","span":{"begin":189,"end":194},"obj":"Species"}],"attributes":[{"id":"A1","pred":"db_id","subj":"1","obj":"9606"},{"id":"A19","pred":"db_id","subj":"19","obj":"9606"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":628,"end":631},"obj":"Glycan_Motif"},{"id":"T3","span":{"begin":747,"end":750},"obj":"Glycan_Motif"},{"id":"T5","span":{"begin":958,"end":961},"obj":"Glycan_Motif"},{"id":"T7","span":{"begin":971,"end":975},"obj":"Glycan_Motif"},{"id":"T9","span":{"begin":980,"end":984},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G98544DH"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81928IQ"},{"id":"A3","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G98544DH"},{"id":"A4","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81928IQ"},{"id":"A5","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G98544DH"},{"id":"A6","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81928IQ"},{"id":"A7","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G93468NI"},{"id":"A8","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68110IF"},{"id":"A9","pred":"image","subj":"T9","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G18625KA"},{"id":"A10","pred":"image","subj":"T9","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G17077FL"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"sentences","denotations":[{"id":"T1","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"T2","span":{"begin":107,"end":273},"obj":"Sentence"},{"id":"T3","span":{"begin":274,"end":288},"obj":"Sentence"},{"id":"T4","span":{"begin":289,"end":291},"obj":"Sentence"},{"id":"T5","span":{"begin":292,"end":481},"obj":"Sentence"},{"id":"T6","span":{"begin":482,"end":784},"obj":"Sentence"},{"id":"T7","span":{"begin":785,"end":985},"obj":"Sentence"},{"id":"T8","span":{"begin":986,"end":1172},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"T2","span":{"begin":107,"end":273},"obj":"Sentence"},{"id":"T3","span":{"begin":274,"end":288},"obj":"Sentence"},{"id":"T4","span":{"begin":289,"end":291},"obj":"Sentence"},{"id":"T5","span":{"begin":292,"end":481},"obj":"Sentence"},{"id":"T6","span":{"begin":482,"end":784},"obj":"Sentence"},{"id":"T7","span":{"begin":785,"end":985},"obj":"Sentence"},{"id":"T8","span":{"begin":986,"end":1172},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":628,"end":631},"obj":"https://glytoucan.org/Structures/Glycans/G81928IQ"},{"id":"T2","span":{"begin":628,"end":631},"obj":"https://glytoucan.org/Structures/Glycans/G98544DH"},{"id":"T3","span":{"begin":747,"end":750},"obj":"https://glytoucan.org/Structures/Glycans/G81928IQ"},{"id":"T4","span":{"begin":747,"end":750},"obj":"https://glytoucan.org/Structures/Glycans/G98544DH"},{"id":"T5","span":{"begin":958,"end":961},"obj":"https://glytoucan.org/Structures/Glycans/G81928IQ"},{"id":"T6","span":{"begin":958,"end":961},"obj":"https://glytoucan.org/Structures/Glycans/G98544DH"},{"id":"T7","span":{"begin":971,"end":975},"obj":"https://glytoucan.org/Structures/Glycans/G68110IF"},{"id":"T8","span":{"begin":971,"end":975},"obj":"https://glytoucan.org/Structures/Glycans/G93468NI"},{"id":"T9","span":{"begin":980,"end":984},"obj":"https://glytoucan.org/Structures/Glycans/G17077FL"},{"id":"T10","span":{"begin":980,"end":984},"obj":"https://glytoucan.org/Structures/Glycans/G18625KA"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":971,"end":975},"obj":"http://www.glycoepitope.jp/epitopes/EP0066"},{"id":"T2","span":{"begin":980,"end":984},"obj":"http://www.glycoepitope.jp/epitopes/EP0069"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"Glycosmos6-MAT","denotations":[{"id":"T1","span":{"begin":622,"end":627},"obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"T2","span":{"begin":741,"end":746},"obj":"http://purl.obolibrary.org/obo/MAT_0000098"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":387,"end":392},"obj":"Glycan"},{"id":"T2","span":{"begin":628,"end":631},"obj":"Glycan"},{"id":"T3","span":{"begin":747,"end":750},"obj":"Glycan"},{"id":"T4","span":{"begin":902,"end":907},"obj":"Glycan"},{"id":"T5","span":{"begin":958,"end":961},"obj":"Glycan"},{"id":"T6","span":{"begin":971,"end":975},"obj":"Glycan"},{"id":"T7","span":{"begin":980,"end":984},"obj":"Glycan"},{"id":"T8","span":{"begin":1033,"end":1038},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A9","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G98544DH"},{"id":"A10","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G98544DH"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G98544DH"},{"id":"A11","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G98544DH"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A12","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A5","pred":"glycosmos_id","subj":"T5","obj":"https://glycosmos.org/glycans/show/G98544DH"},{"id":"A13","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G98544DH"},{"id":"A6","pred":"glycosmos_id","subj":"T6","obj":"https://glycosmos.org/glycans/show/G68110IF"},{"id":"A14","pred":"image","subj":"T6","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G68110IF"},{"id":"A7","pred":"glycosmos_id","subj":"T7","obj":"https://glycosmos.org/glycans/show/G18625KA"},{"id":"A15","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G18625KA"},{"id":"A8","pred":"glycosmos_id","subj":"T8","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A16","pred":"image","subj":"T8","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"Anatomy-MAT","denotations":[{"id":"T1","span":{"begin":622,"end":627},"obj":"Body_part"},{"id":"T2","span":{"begin":741,"end":746},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000098"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":28,"end":36},"obj":"Phenotype"},{"id":"T2","span":{"begin":211,"end":215},"obj":"Phenotype"},{"id":"T3","span":{"begin":292,"end":298},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0002861"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0001658"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"HP:0002664"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"T2","span":{"begin":195,"end":204},"obj":"Disease"},{"id":"T3","span":{"begin":292,"end":298},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005105"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005105"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":387,"end":392},"obj":"Glycan"},{"id":"T2","span":{"begin":628,"end":631},"obj":"Glycan"},{"id":"T3","span":{"begin":747,"end":750},"obj":"Glycan"},{"id":"T4","span":{"begin":902,"end":907},"obj":"Glycan"},{"id":"T5","span":{"begin":958,"end":961},"obj":"Glycan"},{"id":"T6","span":{"begin":971,"end":975},"obj":"Glycan"},{"id":"T7","span":{"begin":980,"end":984},"obj":"Glycan"},{"id":"T8","span":{"begin":1033,"end":1038},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A9","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G98544DH"},{"id":"A10","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G98544DH"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G98544DH"},{"id":"A11","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G98544DH"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A12","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A5","pred":"glycosmos_id","subj":"T5","obj":"https://glycosmos.org/glycans/show/G98544DH"},{"id":"A13","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G98544DH"},{"id":"A6","pred":"glycosmos_id","subj":"T6","obj":"https://glycosmos.org/glycans/show/G68110IF"},{"id":"A14","pred":"image","subj":"T6","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G68110IF"},{"id":"A7","pred":"glycosmos_id","subj":"T7","obj":"https://glycosmos.org/glycans/show/G18625KA"},{"id":"A15","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G18625KA"},{"id":"A8","pred":"glycosmos_id","subj":"T8","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A16","pred":"image","subj":"T8","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":971,"end":975},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T2","span":{"begin":980,"end":984},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0066"},{"id":"A2","pred":"glycoepitope_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0069"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T1","span":{"begin":28,"end":36},"obj":"Phenotype"},{"id":"T2","span":{"begin":292,"end":298},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0002861"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0002664"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T1","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"T2","span":{"begin":292,"end":298},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"MONDO:0005105"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"MONDO:0004992"}],"namespaces":[{"prefix":"MONDO","uri":"http://purl.obolibrary.org/obo/MONDO_"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":971,"end":975},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T2","span":{"begin":980,"end":984},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0066"},{"id":"A2","pred":"glycoepitope_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0069"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"T2","span":{"begin":107,"end":481},"obj":"Sentence"},{"id":"T3","span":{"begin":482,"end":784},"obj":"Sentence"},{"id":"T4","span":{"begin":785,"end":985},"obj":"Sentence"},{"id":"T5","span":{"begin":986,"end":1172},"obj":"Sentence"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":622,"end":627},"obj":"Body_part"},{"id":"T3","span":{"begin":741,"end":746},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A2","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_6110636"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A4","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_6110636"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-FMA","denotations":[{"id":"T1","span":{"begin":622,"end":627},"obj":"Body_part"},{"id":"T2","span":{"begin":741,"end":746},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"FMA:50801"},{"id":"A2","pred":"db_id","subj":"T2","obj":"FMA:50801"}],"namespaces":[{"prefix":"FMA","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"GlyCosmos15-MAT","denotations":[{"id":"T1","span":{"begin":622,"end":627},"obj":"Body_part"},{"id":"T2","span":{"begin":741,"end":746},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000098"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":189,"end":194},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":622,"end":627},"obj":"Body_part"},{"id":"T3","span":{"begin":741,"end":746},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A2","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_6110636"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A4","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_6110636"}],"text":"Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.\nA monoclonal IgM antibody, 4.2, reacting with a surface antigen expressed on most human melanomas (Yeh, M.-I., Hellström, I., Abe, K., Hakomori, S., and Hellström, K. E. (1982) Int. J. Cancer, 29, 269-275) was shown to be directed to a ganglioside with the carbohydrate structure NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc beta 1 leads to 1Cer. The carbohydrate structure, established by enzymatic degradation and methylation analysis with mass spectrometry, is identical with that of brain GD3 ganglioside, but its ceramide is characterized by a predominance of longer chain fatty acids, in contrast to brain GD3 that has mainly C18:0 fatty acid. The antibody did not react with various other gangliosides, including those having the same terminal sugar sequence (NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal) as GD3, such as GT1a and GQ1b. Its specificity is therefore restricted to the NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3Gal beta 1 leads to 4Glc leads to Cer sequence, including the innermost sugar, Glc residue."}